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Magnetic Resonance Labeling of Stem Cells
Is Positive Tracking a Plus or a Minus?*
Dara L. Kraitchman, VMD, PHD,† Peter Caravan, PHD‡
Baltimore, Maryland; and Boston, MassachusettsRecent meta-analyses of clinical cellular therapy
trials in cardiovascular disease have shown that
these therapies are safe and perhaps yield a positive
therapeutic benefit (1–5). However, 1 issue that has
plagued these clinical studies is the inability to
determine the percentage engraftment of exog-
enously administered stem cells and the stem cell
fate. In this issue of iJACC, Adler et al. (6) propose
a cardiac magnetic resonance (CMR) contrast based
on a paramagnetic agent, gadolinium, to track the
engraftment of embryonic stem cell-derived cardio-
vascular progenitor cells.
See page 1114
Because of the high spatial resolution and soft
tissue detail, CMR is ideally suited for imaging the
myocardium. Thus, when techniques for direct
labeling of stem cells with iron oxides for tracking
stem cell engraftment using CMR were developed
in the 1990s (7,8), they were rapidly adopted for
cardiac use. Later methods using Food and Drug
Administration-approved superparamagnetic iron
oxides to label cells were hoped to speed clinical
translation. However, adoption rates have been low.
In part, this may be due to the negative image
contrast provided by iron oxide-labeled cells. Dis-
criminating hypointensities from labeled cells from
other causes of signal loss, e.g., calcium, hemor-
rhage, or metallic implants, may be difficult. Fur-
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.
From the †Russell H. Morgan Department of Radiology and Radiological
Science, Johns Hopkins University School of Medicine, Baltimore,
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Massachusetts General Hospital, Harvard Medical School, Boston, Mas-
sachusetts. Dr. Kraitchman has received research materials (but not
Gadofluorine M) from Bayer Pharma Healthcare.thermore, the loss of signal from iron-labeled cells
obscures the underlying anatomy. Although tech-
niques to convert the negative contrast produced by
iron oxides to hyperintensities or positive contrast
have been developed, these techniques are often
difficult to implement and may lack sensitivity
(9–11).
The overwhelming majority of CMR contrast
agent usage today is gadolinium-based agents that
provide positive image contrast. Because CMR is a
signal-starved technique with many CMR artifacts
resulting in a signal loss, contrast agents that enhance
signal are valued. Although most contrast-enhanced
CMR is performed with a pre-contrast scan in order
to identify the effect of the contrast agent on the
image, imaging of CMR-labeled cells is performed
days after cells transplantation. Positive-contrast
cell tracking would be beneficial when no reference
scan is available.
However, contrast agents are not just black and
white. The mechanism of contrast generation dif-
fers between iron oxide-based T2 agents and
gadolinium-based T1 agents. Gadolinium probes
need direct access to water to alter image contrast.
In cell labeling, if the contrast agent is restricted to
an endosomal compartment, then it will have little
effect on most of the cellular water since water
exchange in and out of the endosome is slow. On
the other hand, contrast agent distributed through
the cytosol will have a much stronger effect on T1.
It appears that the chemical structure of the contrast
agent as well as the means of cell uptake (e.g.,
pinocytosis vs. electroporation) strongly influence
the relaxation properties of the labeled cell (12). A
benefit of iron oxide probes is that they shorten T2*
via a through-space mechanism; strong signal loss is
observed regardless of the cellular location of the
contrast agent.
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1124Adler et al. (6) use a bimodal probe containing a
arbocyanine dye and a gadolinium chelate to label
mbryonic stem cell-derived cardiovascular progenitor
ells and track these cells in the myocardium. This
o-called gadofluorine probe, Gadofluorine M
GdFM) has been previously reported for cell labeling
nd tracking studies in the brain (13,14). Prior work
evealed that the probe is distributed throughout the
ytosol and has excellent T1 relaxation properties
13,14). Adler et al. (6) extend this work to the
yocardium and demonstrate that positive contrast
an be used to track cells in the heart with this probe.
n the current study, the authors work at very high
eld, 9.4-T, which is well suited to cardiac imaging in
ice. However, at clinical field strengths, e.g., 1.5- or
.0-T, the sensitivity should be much higher, as many
adolinium-based agents exhibit strong inverse field-
ependent relaxivity. Thus, the conspicuity of the cells
hould improve if used clinically.
There are a few concerns with the present study.
ne of the pitfalls of any direct labeling technique
s whether the label remains trapped in the intra-
ellular space or is released and can be taken up by
ystander cells. Adler et al. (6) have addressed this
oncern by coincubation of cells expressing green
uorescent protein with GdFM-labeled cells. Very
ittle uptake of GdFM by the green fluorescent
rotein-expressing cells was seen.
However, another concern is if the cells should
ie, the contrast agent may either remain in situ orcardial infarction: a meta-analysis of ran- Exp Neurol 1993;1f the label may not represent the originally deliv-
red exogenously labeled cells. Further complicat-
ng the issue is that the mechanism of GdFM
ptake by cells is not well understood. GdFM has
een used in several applications including the
dentification of metastatic cancer in lymph nodes
15,16) and components of the atherosclerotic
laque (17,18). From these studies, one can glean
hat GdFM can be taken up by phagocytic cells,
uch as macrophages, and has an affinity for non-
ipid moieties, such as collagen/fibrous tissue. Since
large number of stem cells die shortly after
dministration, it is likely that the positive contrast
rovided by GdFM may persist long after the
elivered stem cells are no longer there. Finally,
ith any gadolinium-based agent, there is the
otential for the release of free gadolinium as the
ells are degraded. Unchelated gadolinium is highly
oxic. Further pre-clinical and clinical studies are
equired to prove the safety and utility of GdFM
nd this imaging technique. Although GdFM cell
abeling yields a positive MR signal, it is likely that
he utility of this labeling agent will remain in
re-clinical evaluation of stem cell therapies for the
oreseeable future.
eprint requests and correspondence: Dr. Dara L. Kraitch-
an, Russell H. Morgan Department of Radiology and Ra-
iological Science, Johns Hopkins University School of Med-
cine, 600 North Wolfe Street, 314 Park Building, Baltimore,be taken up by bystander cells. Thus, the presence Maryland 21287. E-mail: dara@mri.jhu.edu.1
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